10x visium spatial transcriptomics data (Spatial Transcriptomics Inc)
Structured Review

10x Visium Spatial Transcriptomics Data, supplied by Spatial Transcriptomics Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/10x visium spatial transcriptomics data/product/Spatial Transcriptomics Inc
Average 86 stars, based on 1 article reviews
Images
1) Product Images from "Histology and spatial transcriptomic integration revealed infiltration zone with specific cell composition as a prognostic hotspot in glioblastoma"
Article Title: Histology and spatial transcriptomic integration revealed infiltration zone with specific cell composition as a prognostic hotspot in glioblastoma
Journal: bioRxiv
doi: 10.1101/2025.10.08.681087
Figure Legend Snippet: (a) Overview of the clustering approach and characterization of identified regions. i) Features are extracted from each tiles of H&E slides using the histology foundation model H-optimus-0. ii) Tile features from each slide are clustered using K-means, trained on the discovery cohort (cohort A) and applied to the validation cohorts (cohorts B and C). iii) Expert neuropathologists review and annotate each cluster to define distinct regions. (b) Methods overview. Left : Graphical representation of the methods used to align paired H&E and Visium spatial transcriptomics for cell type annotation in 31 samples from Cohort B from the MOSAIC consortium. Right: Overview of the method used to categorize tiles according to their tile score and tile prediction in 3 classes: high score + high prediction = Long Survival, high score + low prediction = Short Survival, all others = Non-informative. (c) Schematic representation of common spatial arrangements of the regions within tumor sections. (d) Proportion of tiles associated with short survival, long survival, and non-informative categories in the validation cohort in the different regions (excluding the 4 regions with necrosis, hemorrhage, and artefacts) (cohorts B and C). (e) Distribution of regions among Long Survival and Short Survival tiles in the validation cohorts (cohorts B and C). (f) Average of cell count per cell type in the different tissue regions as estimated using the output weights of the cell2loc deconvolution algorithm and 31 samples from cohort B with paired H&E, Visium spatial transcriptomics, and scRNAseq. Rare cell types (median counts < 0.1) were excluded.
Techniques Used: Biomarker Discovery, Cell Counting
Figure Legend Snippet: (a) Distributions of the number of nuclei per tile and the median nuclear area per tile across 457 samples in cohort A (training dataset). Only tiles with a tile score > 0 were included. Purple lines denote thresholds optimized on the training set; arrows indicate the direction associated with shorter survival. *** indicates p value < 0.001 for a Mann Whitney U test between two boxplots. (b) Proportion of biomarker-positive tiles defined as infiltrated white matter (liWM) regions with >30 nuclei and a median nuclear area <40 µm² among all tumor tiles in short- and long-surviving patients from cohorts B and C (testing dataset). (c) Representative H&E slide and corresponding Visium spatial transcriptomics overlay (validation dataset) showing biomarker positive liWM tiles (dark purple) in comparison to adjacent liWM tissue (purple). (d) Cell type composition per tile in biomarker-positive liWM tiles versus non informative liWM tiles in the n=31 patients of the MOSAIC dataset. Cell types with median count per tile <0.1 were excluded for clarity. (e) Pathways enriched in short survival liWM vs non informative liWM. Raster plot of GSEA showing leading genes of each pathways by log2FoldChange. Only pathways with FDR<0.2 were included (See GSEA results and all genes in Supplementary table I and Table J [Supplementary material]). (f) Volcano plot for DEA of short survival liWM vs non informative liWM.
Techniques Used: MANN-WHITNEY, Biomarker Discovery, Comparison
Figure Legend Snippet: (a). In cohort A, proportion of tiles associated with short survival, long survival, and non-informative categories in pooled tissue subtypes Tumor 1.0, Tumor 1.1, and Tumor 2.1. (b). Within pooled tissue subtypes Tumor 1.0, Tumor 1.1, and Tumor 2.1, distributions of nuclear morphology features like nuclear density (number of nuclei per tile) and nuclear size (median nuclear area in µm²) and median nuclear circularity. (c) Representative images of the annotated vessels subtypes patterns on H&E slides (20X): (i) thin endothelium capillary (TEC), (ii) hyperplasic endothelium capillary (HEC), (iii) Microvascular Proliferation (MVP) (iv) Thin Endothelium Wide Lumen (TEWL) (v) Hyperplasic Endothelium Wide Lumen (HEWL) (d) Relative ratios of tiles with vessels or specific vessels subtypes within tumor regions (1.0, 1.1 and 2.1) for each patients across the two survival group (2y < OS and OS > 3y). Distributions are computed for the training set (cohort A) and validation set (cohort B&C). Vessels presence and vessels subtypes detection are obtained after inference by the vessels detection and vessels subtypes classifier models on the entire cohorts. (e) Distribution of cell count per cell type in the tumor regions (1.0, 1.1 and 2.1) for short-survival, long-survival and non-informative tiles. Distributions of cell counts statistically significantly different (Mann–Whitney test; threshold at 0.05) are indicated with a star. 31 samples from Cohort B with paired H&E, Visium spatial transcriptomics, and scRNAseq were used. Cell types with low range of mean count variations across tissue regions were removed for clarity. (f) Illustration of the pathway enrichment analyses of the differential expressed genes between long- and short-survival. Negative fold change is associated with worse survival outcomes and positive with better survival outcomes. (See GSEA results and all genes in supplementary table L [Supplementary material])
Techniques Used: Biomarker Discovery, Cell Counting, MANN-WHITNEY